SubsidieMeestersDeveloping a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.
Projectdetails
Introduction
GeneCode is developing a novel anti-PD drug that contains a central nervous system penetrant compound imitating GDNF peptide pathway activation. This drug aims to alleviate both motor and non-motor symptoms in PD patients, protecting and restoring lesioned dopamine neurons as well as potentially increasing dopamine levels in brain tissue.
Unique Solution
GeneCode's unique solution uses small-molecule compounds that:
- Penetrate the blood-brain barrier
- Target the GFL receptor complex (containing GDNF protein)
- Mimic GFL (GDNF family of ligands) biological effects in neurons
These compounds promote survival in the affected dopaminergic neuronal pathways.
Administration
Once fully developed, the PD drug would be administered weekly or less frequently as an oral treatment.
Broader Applications
Considering the importance of GDNF family ligands and/or RET-signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited to PD. They can also be applied to cure other medical conditions such as:
- Neuropathic pain
- Addiction
- ALS
- Other potential conditions
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.636.639 |
| Totale projectbegroting | € 2.338.056 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- GENECODE ASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Revolutionary therapeutic treatment for stopping progression of Parkinson's diseaseHerantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Gate2Brain. Medicines beyond barriers.Gate2Brain develops peptide-shuttles to transport therapeutic drugs across the blood-brain barrier, aiming to treat CNS disorders, particularly pediatric brain tumors. | EIC Accelerator | € 2.470.759 | 2023 | Details |
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Homeoproteins as novel therapies for neurodegenerative diseasesBrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Gate2Brain. Medicines beyond barriers.
Gate2Brain develops peptide-shuttles to transport therapeutic drugs across the blood-brain barrier, aiming to treat CNS disorders, particularly pediatric brain tumors.
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
Homeoproteins as novel therapies for neurodegenerative diseases
BrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel small molecule attenuator of neuroinflammation in Parkinson’s DiseaseNEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap. | ERC Proof of... | € 150.000 | 2025 | Details |
Development of TW002 (AAV5--GDNF) for the Treatment of Amyotrophic Lateral SclerosisHet project onderzoekt de veiligheid en effectiviteit van de gentherapie TW002 voor ALS, met als doel de symptomen te verlichten en de levensduur en kwaliteit van leven van patiënten te verbeteren. | Mkb-innovati... | € 200.000 | 2015 | Details |
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic DiseasesDevelop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment. | ERC Advanced... | € 2.495.250 | 2022 | Details |
COMMERCIALISATION OF A NOVEL PROTEIN VARIANT WITH NEURORESTORATIVE EFFECTS FOR AMYOTROPHIC LATERAL SCLEROSISREGENERA aims to evaluate the feasibility of the C-MANF peptide as a novel, accessible treatment for ALS, potentially improving patient outcomes and offering a new therapeutic avenue. | ERC Proof of... | € 150.000 | 2022 | Details |
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATIONREGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration. | EIC Pathfinder | € 2.943.233 | 2024 | Details |
Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease
NEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap.
Development of TW002 (AAV5--GDNF) for the Treatment of Amyotrophic Lateral Sclerosis
Het project onderzoekt de veiligheid en effectiviteit van de gentherapie TW002 voor ALS, met als doel de symptomen te verlichten en de levensduur en kwaliteit van leven van patiënten te verbeteren.
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic Diseases
Develop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment.
COMMERCIALISATION OF A NOVEL PROTEIN VARIANT WITH NEURORESTORATIVE EFFECTS FOR AMYOTROPHIC LATERAL SCLEROSIS
REGENERA aims to evaluate the feasibility of the C-MANF peptide as a novel, accessible treatment for ALS, potentially improving patient outcomes and offering a new therapeutic avenue.
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.